Redbud is excited to join two collaborative development projects in biomanufacturing. Led by scientists at MIT and Villanova–and alongside partners at Genentech, Merck, and Millipore Sigma–projects include a transcriptome-based model for improved CAR-T therapy and a nanofluidic platform for bioprocess monitoring. These projects are part of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to address challenges in biomanufacturing and personalized medicine.

For more information, visit the NIIMBL project announcement page.